Innovation in diagnostics
Where science, technology, and expertise meet
As a globally defining player in liquid biopsy, our goal is to improve the recovery chances of cancer patients worldwide using cutting-edge genetic technologies, cloud-based IT solutions, and decades of molecular biology experience.
Our Professional Competencies
Our professional competencies
Integrated, multi-disciplinary expertise in the service of biotechnology.
Genomic IT expertise
Our software developers have more than 20 years of combined professional experience in designing the architecture of high-throughput, cloud-based data analysis systems, guaranteeing the scalable and secure processing of genomic data.
✔ Designing scalable NGS analysis pipelines✓ Orchestrating high-throughput workflows.✓ Enabling distributed genomic data processing✓ Automating reproducible analyses✓ Managing large-scale sequencing data✓ Ensuring data integrity and traceability✔ Securing sensitive genomic information✔ Monitoring performance and reliability✔ Evaluation of the completed resultResearch Excellence
Our leading researchers have more than fifteen years of experience in NGS-based tumor diagnostics, molecular biomarkers and bioinformatic analysis.
P. Katalin
0+
Years of Combined Experience
Scientific Advisory Board
Composed of internationally recognized experts with professional performance demonstrated in publications and clinical translation — spanning from the molecular pathogenesis of tumors to therapeutic biomarker validation.
Team Coordination
Our experienced office manager ensures the synergy of molecular biology, medical biotechnology, and IT professionals with refined organizational and coordination competencies, supporting the high-quality implementation of projects.
Technology
Cutting-edge technology in oncology
Next-generation sequencing (NGS) is the international gold standard for complex genomic studies, enabling comprehensive characterization of tumors and precision diagnostics.
What could be more forward-looking than being able to uncover the molecular cause of a disease beyond its recognition — revealing why and how it develops, thereby identifying its weak points.
Technology background
Two Decades of NGS Experience in Oncology
Our team has nearly two decades of expertise and is among the early pioneers of NGS-based cancer research in Hungary. Today, NGS forms the foundation of modern oncology — enabling comprehensive characterization of tumors, the clinical results of liquid biopsy, and precision diagnostics.
0+
Years of NGS Experience
0+
Genetic analysis
Innovation is our calling
For us, innovation is not a self-serving technological race, but consistent, responsible work. We are working on the development of research and diagnostic solutions that are interpretable and applicable in everyday clinical practice — where they can provide real added value.
Research in recent years — including our own contribution — has enabled significant progress in the treatment of many cancers. Molecular diagnostics today often helps in selecting targeted therapies, avoiding unnecessarily burdensome treatments, and more accurately tracking disease progression.
What we commit to is scientific rigor, responsible development, and honest communication. With our research, we contribute to the progress that has made more accurate diagnostics and more effective treatment options available for many types of cancer today.
These results are the fruit of the joint, long-term work of the scientific community.
We believe that true innovation is born from knowing both the possibilities and the limits. That is why we communicate transparently, work according to strict professional principles, and contribute to the progress that today makes a tangible difference for many patients.
We are aware that genetic diagnostics is not a universal solution. It does not provide clear answers for every type of cancer, and not every clinical situation leads to direct therapeutic decisions. Not every tumor carries molecular alterations that can currently be treated with targeted therapy, and not every clinical situation results in a direct therapeutic decision from genetic information.
The goal of our work is not to promise solutions to every question, but to provide accurate, reliable molecular information where it has proven significance.